Archives
-
Curcumol, SAM, and Autophagy in Liver Fibrosis
2026-09-21
A 2026 study links curcumol-induced hepatic stellate cell death to disruption of methionine metabolism, placing MAT2A, AHCY, and S-adenosylmethionine within an autophagy-related antifibrotic mechanism. Pharmacological inhibition, ATG7 silencing, and SAM rescue experiments provide a useful framework for separating correlation from functional pathway involvement in liver fibrosis research.
-
Imatinib Hydrochloride: A New Kinase Question
2026-09-21
Imatinib hydrochloride remains a powerful model for studying oncogenic tyrosine kinase signaling, but emerging phosphatase research suggests that catalytic inhibition may be only one layer of biological control. This article translates that insight into a practical, translational workflow for chronic myelogenous leukemia and gastrointestinal stromal tumor research while distinguishing established evidence from testable hypotheses.
-
2-NBDG Glucose Uptake Assay Kit Guide
2026-09-20
This scenario-based guide explains how SKU K2212 supports reproducible, non-radioactive measurement of cellular glucose uptake in viability, cytotoxicity, and metabolism studies. It covers assay principle, controls, 96-well workflow design, interpretation limits, and practical product-selection criteria.
-
KR-12 (human) TFA: Reliable Assay Design
2026-09-19
Learn how KR-12 (human) TFA, SKU C8754, can support better-controlled antimicrobial, viability, proliferation, and cytotoxicity workflows. This scenario-based guide connects peptide formulation, concentration planning, assay controls, and interpretation to published KR-12 biology.
-
Mechanical Stress, Cytoskeleton, and Autophagy
2026-09-19
The reference study shows that autophagy induced by cellular compression depends primarily on cytoskeletal microfilaments, while microtubules provide supporting functions. Its combined use of mechanical loading, cytoskeletal perturbation, fluorescence imaging, and western blotting offers a practical framework for dissecting force-dependent autophagy and mechanotransduction.
-
AS1842856 Foxo1 Inhibitor: Mechanism & Workflow
2026-09-18
AS1842856 is a Foxo1 inhibitor reported to reduce Foxo1 activity without lowering Foxo1 protein abundance. Its documented effects on gluconeogenic gene expression, hepatic glucose production, and autophagy-related activity support controlled metabolic and type 2 diabetes research workflows.
-
RGFP966: From HDAC3 Modulation to HO-1 Insight
2026-09-17
RGFP966 can serve as a mechanistic perturbation tool for testing how HDAC3-linked regulation intersects with HO-1 enzyme activity. Paired with the AMC-Hem activity probe described in the reference study, it supports a translational workflow that separates HO-1 abundance from catalytic function in macrophage and vascular research.
-
Platycodin D Targets RFC4 in Lung Cancer
2026-09-17
This pre-proof study combines thermal proteome profiling, local stability mapping, and proteomic analyses to identify RFC4 as a candidate binding target of Platycodin D in non-small cell lung cancer. Its findings connect RFC4 engagement with reduced Notch1/Notch3 signaling, altered ubiquitination, and apoptosis, providing a target-to-pathway framework for mechanistic drug research.
-
CAY10499: Mapping Lipid Hydrolysis in TAMs
2026-09-16
CAY10499, an inhibitor of human hormone sensitive lipase and monoglyceride lipase, can help separate lipid hydrolysis from ACLY-driven fatty-acid synthesis in macrophage studies. This article develops an assay strategy for interpreting tumor-associated macrophage metabolism without conflating mechanistically distinct lipid pathways.
-
EZ Cap™ Cas9 mRNA (5-moUTP) Workflow Guide
2026-09-16
Build transient CRISPR-Cas9 genome editing workflows for zebrafish neurodegeneration and cell-based functional gene studies with a capped, modified Cas9 mRNA. This guide connects the Fyn–Stat3 neurodegeneration model to practical delivery, control, optimization, and troubleshooting decisions.
-
Moxifloxacin Workflows for Gyrase and Toxicity
2026-09-15
Moxifloxacin supports a connected workflow spanning bacterial DNA gyrase studies, mammalian cell viability assays, and antibiotic-associated metabolic research. This guide translates the product’s physicochemical profile and the reference study’s topoisomerase findings into practical assay design, controls, and troubleshooting decisions.
-
Tofacitinib Repairs RA Macrophage Dysfunction
2026-09-15
The 2026 reference study identifies GM-CSF-reprogrammed rheumatoid arthritis macrophages as an inflammatory and metabolically stressed population marked by STAT5 activity, oxidative stress, and mitochondrial fragmentation. It shows that Tofacitinib can reverse this state more broadly than tested metabolic interventions by reducing GM-CSFRα-associated signaling and restoring regulatory, mitochondrial, and oxidative phosphorylation features.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-09-14
The bioRxiv preprint argues that degradation of RNA polymerase II can activate cell death through a mechanism that is not explained solely by the resulting loss of transcription. This distinction is important for interpreting transcription-targeting experiments, selecting mechanistically appropriate controls, and separating polymerase depletion from transcriptional inhibition in cancer research.
-
Nullscript: Histone Deacetylase Inhibitor Guide
2026-09-14
Nullscript offers a practical way to interrogate HDAC-dependent biology without treating transcriptional reporter activation as the sole readout. This guide connects its cardiac ischemia/reperfusion application with placental mitochondrial research, providing assay design, workflow, and troubleshooting strategies.
-
7-Ethyl-10-hydroxycamptothecin Workflow Guide
2026-09-13
Build reproducible colon cancer assays around 7-Ethyl-10-hydroxycamptothecin by separating topoisomerase I damage from emerging FUBP1/FUSE biology. This workflow combines dose-response design, cell-cycle analysis, apoptosis measurements, and orthogonal mechanistic validation for advanced colon cancer research.